{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:F4JCU0",
      "entity_text" : "SUA",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_E031" ],
      "Organ" : [ "uberon:UBERON:0007023" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "This 24-week, phase 3, multicenter, randomized, double-blind, double-dummy, active controlled, three-arm, parallel-group, non inferiority study assessed the efficacy and safety of once-daily oral febuxostat (40 mg/day or 80 mg/day) compared with allopurinol 300 mg/day in reducing SUA levels in adults from China with hyperuricemia with or without gout (trial registration number JapicCTI-132106).",
  "reading_complete" : "2020-07-28T17:22:01Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T17:15:21Z",
  "trigger" : "levels",
  "evidence" : [ "SUA levels" ],
  "pmc_id" : "6858416",
  "score" : 0
}